ADC Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Biopôle 3b, Epalinges, Vaud, 1066, Switz...Phone Number
+41 216530200Website
www.adctherapeutics.comRevenue
$79.6 MillionStock Symbol
ADCTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ADC Therapeutics
ADC Therapeutics SA is a global biotechnology company focused on the discovery, development, commercialization, and advancement of antibody drug conjugate therapies for the treatment of cancer. The company specializes in creating targeted oncology medicines designed to selectively attack cancer cells while minimizing the impact on healthy tissue. By combining advanced antibody engineering with potent therapeutic payloads, ADC Therapeutics develops innovative treatments intended to improve clinical outcomes for patients facing difficult-to-treat cancers.Explore more
ADC Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ADC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ADC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ADC Therapeutics recently announced quarterly report
Product Launch: Get notified when ADC Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if ADC Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ADC Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at ADC Therapeutics
Check out if ADC Therapeutics is spiking on competitors!
ADC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
ADC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ADC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ADC Therapeutics.
ADC Therapeutics financials insights
Gather financial insights about ADC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$40M
2015
Unspecified
$80M
2016
Share Placement
$105M
Series D
$105M
2019
Series E
$303M
2020
Stock Offering
$267.6M
2022
Private Equity
$6.3M
Debt
$175M
2025
Stock/Share Issuance
$100M
ADC Therapeutics Tech Stack
A closer look at the technologies used by ADC Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Regulations
Person-Based
Compliance, Regulations
Earnings
ADC Therapeutics has reported cost of product sales of $2.3 million for Q2 2026 and $6 million for the six months ended June 30, 2026, compared to $0.8 million and $2.9 million for the same periods in 2025, with the increases primarily driven by a shift in personnel focus from R&D clinical supply activities to commercial manufacturing activities.
Earnings, Research & Development, Finance
Earnings
Earnings, Finance, Financial Operations
ADC Therapeutics News & Media
ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses
On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […]ADC Therapeutics narrows loss as ZYNLONTA sales grow | ADCT Quarterly Report (10-Q)
Net revenue reached $40.1M in H1 2026 while net loss fell to $49.5M. ADC Therapeutics details LOTIS-5 PFS benefit, FDA concerns, heavy royalty debt and a new 17% restructuring.ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsNicole Riley - Head of Investor Relations & Corporate...ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ADC Therapeutics
Sign Up For FreeTo access detailed company insights
ADC Therapeutics SA is a global biotechnology company focused on the discovery, development, commercialization, and advancement of antibody drug conjugate therapies for the treatment of cancer. The company specializes in creating targeted oncology medicines designed to selectively attack cancer cells while minimizing the impact on healthy tissue. B... Read More
